Research Interests
My research interests include innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer, the immunophenotype of the tumor microenvironment, and biomarkers to direct therapy in gynecologic cancers for over 25 years.
Selected Grants
The Duke University - Duke Cancer Institute National Clinical Trials Network Lead Academic Participating Site (UG1) Support Grant
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2032FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovaria
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2026 - 2031CATALINA-4: PHASE 1B/2 STUDY OF TORL-1-23 WITH NEOADJUVANT CHEMOTHERAPY AND INTERVAL CYTOREDUCTIVE SURGERY IN NEWLY DIAGNOSED PATIENTS WITH ADVANCED STAGE OVARIAN CANCER
Clinical TrialPrincipal Investigator · Awarded by TORL BioTherapeutics, LLC · 2026 - 2031A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Clinical TrialPrincipal Investigator · Awarded by Genmab US, Inc. · 2026 - 2031A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline LLC · 2025 - 2030A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Pr
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2025 - 2030A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a DH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2025 - 2030Duke Women's Reproductive Health Research Scholars
Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2020 - 2030Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
Clinical TrialPrincipal Investigator · Awarded by TORL BioTherapeutics, LLC · 2025 - 2030A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2025 - 2030A Phase 3 Randomized, Open-label Study of RinatabartSesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Platinum Resistant Ovarian Cancer
Clinical TrialPrincipal Investigator · Awarded by Genmab US, Inc. · 2025 - 2030A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
Clinical TrialPrincipal Investigator · Awarded by ImmunoGen, Inc. · 2024 - 2029Study of Liquid and Tumor Biopsy Detection of Genomic Alterations and Longitudinal Monitoring of Ovarian Cancer
ResearchPrincipal Investigator · Awarded by Myriad Genetics, Inc. · 2024 - 2029A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician?s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-b
Clinical TrialPrincipal Investigator · Awarded by GOG Foundation · 2024 - 2029A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 WildType, Advanced or Recurrent Endometrial Carcino
Clinical TrialPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2023 - 2028FY23 Ovarian Cancer Research Program - Ovarian Cancer - Clinical Trial Academy Leadership Award.
ResearchPrincipal Investigator · Awarded by University of New Mexico · 2025 - 2028Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal
Clinical TrialPrincipal Investigator · Awarded by ImmunoGen, Inc. · 2023 - 2028A PHASE 1b STUDY OF ZN-c3 IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER
Clinical TrialPrincipal Investigator · Awarded by K-Group Beta, Inc · 2023 - 2028A PHASE 2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF ZN-c3 IN SUBJECTS WITH HIGH-GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
Clinical TrialPrincipal Investigator · Awarded by K-Group Beta, Inc · 2023 - 2028Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR?-positive recurrent platinum-sensitive epithelial ovarian, fallopian
Clinical TrialPrincipal Investigator · Awarded by ImmunoGen, Inc. · 2023 - 2028A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2022 - 2027Building Interdisciplinary Research Careers in Women's Health - BIRCWH
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Arthritis and Musculoskeletal and Skin Diseases · 2002 - 2027A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2022 - 2026Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer - QPT-ORE-004
Clinical TrialPrincipal Investigator · Awarded by OncoQuest Pharmaceuticals Inc. · 2021 - 2026A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent
Clinical TrialPrincipal Investigator · Awarded by GOG Foundation · 2021 - 2026A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY)
Clinical TrialPrincipal Investigator · Awarded by Gynecologic Oncology Group · 2019 - 2026GOG 3025: DUO-O: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Durvalumab (MEDI4736) in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Ad
Clinical TrialPrincipal Investigator · Awarded by Gynecologic Oncology Group · 2019 - 2026NRG NCTN/NCORP - DoD
Clinical TrialPrincipal Investigator · Awarded by NRG Oncology · 2019 - 2026NCORP federal
Clinical TrialPrincipal Investigator · Awarded by NRG Oncology · 2019 - 2026NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
ResearchPrincipal Investigator · Awarded by NRG Oncology · 2017 - 2026NCTN - NCORP non-federal
Clinical TrialPrincipal Investigator · Awarded by NRG Oncology · 2016 - 2026Atezolizumab in Combination with Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients with Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2017 - 2025FRa expression in Endometrial Cancer
ResearchPrincipal Investigator · Awarded by ImmunoGen, Inc. · 2023 - 20251NSPIRE study: Investigating 1L maintenance Niraparib Safety and PatIent management in REal-world ovarian cancer patients (219102)
ResearchPrincipal Investigator · Awarded by GlaxoSmithKline · 2024 - 2025A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tub
Clinical TrialPrincipal Investigator · Awarded by Gynecologic Oncology Group · 2020 - 2025A Novel Preventive Strategy Using Metformin and Megestrol Acetate versus Megestrol Acetate Alone for Endometrial Intraepithelial Neoplasia
ResearchPrincipal Investigator · Awarded by Northwestern University · 2021 - 2025A Novel Preventive Strategy Using Metformin and Megestrol Acetate versus Megestrol Acetate Alone for Endometrial Intraepithelial Neoplasia
ResearchPrincipal Investigator · Awarded by Northwestern University · 2021 - 2025GOG 3107 Rainfol - National Patient Recruitment Video
Public ServicePrincipal Investigator · Awarded by Genmab US, Inc. · 2025 - 2025A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician¿s Choice in Participants with Adva
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2018 - 2024Redox-active drug, BMX-001, as a neuroprotectant: A preventive strategy for chemotherapy induced neurotoxicity
ResearchPrincipal Investigator · Awarded by Health and Environmental Sciences Institute · 2022 - 2024A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
Clinical TrialPrincipal Investigator · Awarded by GOG Foundation · 2021 - 2024A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Clinical TrialPrincipal Investigator · Awarded by ImmunoGen, Inc. · 2022 - 2024Molecular classification of endometrial cancers and association with survival outcomes: GOG-0258
ResearchPrincipal Investigator · Awarded by OhioHealth Research Institute · 2022 - 2024A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 ? platinum resistant disease and are PARP inhibitor naive; Cohort 2 ? had at least 1 prior line of thera
Clinical TrialPrincipal Investigator · Awarded by Ellipses Pharma Limited · 2022 - 2024An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours Harbouring Alterations in the PI3K/AKT/PTEN Pathway
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2021 - 2024Clovis CO3810-101
Clinical TrialPrincipal Investigator · Awarded by Clovis Oncology, Inc. · 2020 - 2024GOG3005-ABB VIE Protocol M13-694: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous
Clinical TrialPrincipal Investigator · Awarded by Gynecologic Oncology Group · 2015 - 2024Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2023SGNTV-002: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2019 - 2023A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS
Clinical TrialPrincipal Investigator · Awarded by I-Mab Biopharma US Limited · 2022 - 2023A PHASE 2 OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF NIRAPARIB AND TSR-042 IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (MOONSTONE)
Clinical TrialPrincipal Investigator · Awarded by Gynecologic Oncology Group · 2019 - 2023A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2018 - 2022GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherpay for the Treatment of Recurrent Plantinum-Resistant Ovarian Canc
Clinical TrialPrincipal Investigator · Awarded by Gynecologic Oncology Group · 2019 - 2022A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Cancers of Muellerian Origin
ResearchPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2016 - 2022Molecular classification of endometrial advanced stage cancers and association with survival outcomes: Ancillary analysis of GOG-0258
ResearchPrincipal Investigator · Awarded by American Association of Obstetricians and Gynecologists Foundation · 2021 - 2022Atezolizumab in Combination with Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients with Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer(Bio-Marker Lab Clinical Research)
ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2018 - 2022A Phase 2 Randomized Double-Blind Trial of Maintenance with Niraparib vs Placebo in Patients with Platinum Sensitive Ovarian Cancer
Clinical TrialPrincipal Investigator · Awarded by TESARO · 2013 - 2021GOG 3020: ATHENA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Clinical TrialPrincipal Investigator · Awarded by Gynecologic Oncology Group · 2019 - 2020A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant
ResearchPrincipal Investigator · Awarded by Marker Therapeutics, Inc. · 2018 - 2020Protocol PR-30-5020-C: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Women with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received at
Clinical TrialPrincipal Investigator · Awarded by TESARO · 2015 - 2020TESARO LUNG AND ENDOMETRIAL CANCER PRACTICUM
Inst. Training Prgm or CMECo-Principal Investigator · Awarded by TESARO · 2019 - 2019Women with BRCA-mutated Advanced Stage Ovarian Cancer
ResearchCo Investigator · Awarded by AstraZeneca LP · 2017 - 2019Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
Clinical TrialPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2016 - 2019Protocol # PM1183-C-004-14: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)
Clinical TrialPrincipal Investigator · Awarded by PharmaMar USA, Inc. · 2015 - 2019NCI National Clinical Trials Network U10 (Year 5)
Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 2014 - 2019An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum Refractory Cervical Carcinoma
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2018 - 2018PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246
Clinical TrialPrincipal Investigator · Awarded by Aprea Therapeutics · 2017 - 2018"A multiple patient early access program for olaparib tablets for the maintenance treatment following response (complete response or partial response) to platinum-based chemotherapy in patients with platinumsensitive relapsed high-grade epithelial ov
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2017 - 2018Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer
ResearchPrincipal Investigator · Awarded by American Association of Obstetricians and Gynecologists Foundation · 2017 - 2018Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients
ResearchInvestigator · Awarded by Gynecologic Oncology Group · 2016 - 2017Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2017Tesaro Ovarian Cancer Practicum
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by TESARO · 2016 - 2016A Phase III Randomized, Double-Blind, Placebo Controlled Multicrentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutaded Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2014 - 2015Fellowships, Gifts & Other Supported Research
2UG1-CA233253-07 NCI National Clinical Trials Network ·
2026
Co-Investigator ·
Awarded by: NCI/NIH
·
$4,777,568.00
The goal of this NCI grant funding is to provide support for ongoing as well as future scientific leadership and clinical trial infrastructure within the Duke Cancer Institute (DCI) in the development and conduct of clinical trials through the National Clinical Trials Network LAPS mechanism. 2026-2032. $634K
A clinical study of raludotatug deruxtecan in people with ovarian cancer (MK-5909-003) ·
2026
Site PI ·
Awarded by: Merck
The primary objectives of this study are to frequency of dose limiting toxicity (phase I) and efficacy based on objective response rate (phase II) of RDX-d combinations in patients with ovarian cancer.
GOG-3128 RAINFOL-03: Study to assess the efficacy and safety of rina-s compared to treatment of investigator's choice in participants with endometrial cancer (RAINFOL-03). ·
2026
Site PI ·
Awarded by: Genmab
The primary objective is to compare progression-free and overall survival outcomes of RINA-S compared to standard of care chemotherapy.
GOG-3119 MK-2870-033 ·
2025
Site PI ·
Awarded by: Merck Sharp & Dohme
The primary objective of this study is to compare sacituzumab tirumotecan in combination with pembrolizumab versus pembrolizumab alone as treatment in mismatch repair proficient endometrial cancer.
Estrogen receptor expression of advanced stage endometrial cancers with wild-type p53 protein expression and associations with survival outcomes and race: Ancillary analysis of GOG-0258 ·
2025
PI ·
Awarded by: Charles B Hammond Fund
·
$10,864.00
Assess estrogen receptor expression of advanced stage endometrial cancers with wild-type p53 protein expression and associations with survival and race
Study of liquid and tumor biopsy detection of genomic alterations and longitudinal monitoring of ovarian cancer ·
2025
PI ·
Awarded by: Myriad
·
$543,330.00
Study of liquid and tumor biopsy detection of genomic alterations and longitudinal monitoring of ovarian cancer” Source: Myriad The primary objective is to evaluate detection of minimal residual disease and genomic alterations based on blood-based circulating tumor DNA.
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer Expressing Claudin 6. ·
2025
Site PI ·
Awarded by: TORL BioTherapeutics, LLC
The primary objective of this study is to assess the efficacy of TORL-1-23 as a monotherapy in women with advanced platinum-resistant ovarian cancer (PROC) expressing CLDN6.
Ovarian Cancer Research Program - Ovarian Cancer - Clinical Trial Academy Leadership Award - Subaward ·
2025
Mentor ·
Awarded by: DOD
·
$114,811.00
The goal is to leverage the four-year commitment by scholars and mentors to build collaborations both within the OCCTA and with ovarian cancer investigators to improve inclusivity and efficiency of clinical trials by advancing innovations in subject recruitment and engagement, biomarker development, and study design and conduct.
NRG Oncology Network Group Operations Center SubAward ·
2025
NRG Investigator Development Committee Chair ·
Awarded by: NCI/NIH
This position entails co-leading the New Investigator's Committee at the two national NRG Oncology meetings per year. In addition, Dr. Secord will be involved in monthly to quarterly meetings for strategic planning, mentoring new investigators, coordinating mentor/mentee activities, and protocol development. Award since 2017.
GOG-3096 DS6000-109: ·
2025
Site PI ·
Awarded by: Daiichi Sankyo Inc
The primary objective of this study is to assess the efficacy of RDX-d as a monotherapy in women with advanced platinum-resistant ovarian cancer.
GOG-3107 RAINFOL-OV2: Phase III trial of RINA-S compared to physician choice standard-of-care in women with recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. ·
2025
Site PI ·
Awarded by: Genmab
The primary objective is to evaluate the efficacy of RINA-S
A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors ·
2025
Site Principal Investigator ·
Awarded by: GSK
·
$1,201,277.00
The primary objective is to evaluate the anticancer activity of GSK5733584 in combination with other anticancer treatments (in each Module) compared to monotherapy GSK5733584.
GOG-3101 MK-2870-020: The primary objective of this study is to compare MK-2870 to Treatment of Physician's Choice (TPC) ·
2024
Site PI ·
Awarded by: Merck
Hypothesis 1: MK-2870 is superior to TPC with respect to OS in participants with high TROP2 expression level. Hypothesis 2: MK-2870 is superior to TPC with respect to OS in all participants.
INSPIRE study: Investigating 1L maintenance niraparib safety and patient management in real-world ovarian cancer patients ·
2024
Site PI ·
Awarded by: GSK
The primary objective is to evaluate the safety of niraparib
MK-2870-005/ENGOT-en23/GOG-3095: A Phase 3, randomized, active-controlled, open-label, multicenter study to compare the efficacy and safety of MK-2870 monotherapy versus treatment of physician's choice in participants with endometrial cancer ·
2024
Site PI ·
Awarded by: Merck
The primary objective is to compare sacituzumab tirumotecan to Treatment of Physician's Choice with respect to progression-free survival and overall survival.
GOG-3072: A Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics and pharmacodynamics of ZN-c3 in combination with other drugs ·
2023
Site PI ·
Awarded by: Zentalis
The primary objective is to evaluate the clinical activity, safety, and tolerability of ZN-c3 with other drugs.
FRalpha expression in endometrial cancer ·
2023
PI ·
Awarded by: ImmunoGen, Inc/Abbvie
·
$83,456.00
Primary goal is to determine expression of FRalpha in endometrial cancer
Evaluation of chemotherapy response and tumor infiltrating lymphocytes in high grade serous carcinomas from the FLORA-6 clinical trial ·
2023
PI ·
Awarded by: CanariaBio Inc.,
·
$129,465.00
Assess tumor infiltrating lymphocytes and other markers of immune response in patients with high grade serous carcinomas treated with oregovomab
GOG-3083/XPORT-EC-042: “A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy in p53 Wild-Type Endometrial Cancer ·
2023
Site PI ·
Awarded by: Karyopharm
The primary objective is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wild type endometrial carcinoma, who have achieved a partial response or complete response after completing at least 12 weeks of platinum-based therapy.
IMGN853-0420: A multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine ·
2023
Site PI ·
Awarded by: Immunogen
The primary objective is to evaluate the efficacy and safety of MIRV in combination with carboplatin followed by MIRV continuation in FRα-positive patients with recurrent platinum-sensitive ovarian cancer
NaPi2b and B7-H4 expression in endometrial cancer ·
2023
PI ·
Awarded by: Mersana Therapeutics
·
$74,535.00
Primary goal is to determine expression of NaPi2b and B7-H4 in endometrial cancer
External Relationships
- AbbVie, Inc.
- AstraZeneca
- Corcept Therapeutics
- Daiichi Sankyo Co., Ltd
- Eisai Pharmaceuticals
- Foundation Medicine, Inc.
- GOG Foundation Board
- GSK
- Genmab
- Gilead Sciences, Inc.
- HistoSonics
- Medtronic (Covidien)
- Merck
- NRG Oncology
- OncoQuest - Quest Pharma
- Project Nana, Inc. Medical Advisory Board
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.